Health
Eisai Completes Rolling Submission to US FDA for LEQEMBI ® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the F
By: investing_za
- Nov 01 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS